Personal record-keeping and educational reference. 18+. The app does not recommend substances, doses or treatment, or determine whether a substance is safe, approved or appropriate for you. Consult a qualified healthcare professional about decisions involving your health.
‹ Library

Survodutide

GLP-1 / MetabolicResearch Use Only

Also known as: BI 456906, GLP-1/glucagon dual agonist

A GLP-1 + glucagon dual agonist in phase-3 trials for obesity and fatty liver disease.

Dosing quick reference

research reference
Starting dose
0.6 mg once weekly
Frequency
Once weekly
Typical range
0.6–6 mg per week
Cycle
12–16+ weeks of slow escalation
Titration (step-up)
0.6 → 1.2 → 1.8 → 2.4 → 3.6 → 4.8 → 6 mg, stepping every 2 weeks
Half-life
~5 days (reported)
Route
Subcutaneous (research)
Common use
Metabolic and liver-health research
Common vial sizes
10 mg
Storage
Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.
Stacking notes
Referenced in research as a single dual-agonist molecule; combining with other incretin agents is not standard in the literature.

Reported side effects

NauseaReduced appetiteGastrointestinal upsetVomiting (reported in trials)
Regulatory note: Investigational; not FDA-approved and not approved in Canada. Phase 3 trials ongoing. Research-grade material is not for human use.
Calculate a dose →Survodutide on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.